Status | Study |
NOT_YET_RECRUITING |
Study Name: Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors Condition: Rhabdoid Tumor Date: 2023-07-11 Interventions: Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with 80% of the RP2D determined in the ongoing pediatric iMA |
Recruiting |
Study Name: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT Condition: Medulloblastoma, Childhood, Recurrent Atypical Teratoid/Rhabdoid Tumor Date: 2016-11-02 Interventions: Biological: Modified Measles Virus |
Recruiting |
Study Name: Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study Condition: Diffuse Large B-cell Lymphoma Follicular Lymphoma Malignan Date: 2016-08-05 Interventions: Drug: Tazemetostat Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine |
Recruiting |
Study Name: Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Condition: Recurrent Childhood Medulloblastoma Recurrent Childhood Ependymoma Date: 2016-02-11 Interventions: Drug: Intra thecal methotrexate |
Recruiting |
Study Name: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Condition: Rhabdoid Tumors INI1-negative Tumors Date: 2015-10-21 Interventions: Drug: Tazemetostat Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine |
Recruiting |
Study Name: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Condition: Malignant Rhabdoid Tumors (MRT) Rhabdoid Date: 2015-10-21 Interventions: Drug: Tazemetostat Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine |
Recruiting |
Study Name: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors Condition: Malignant Rhabdoid Tumor Atypical Teratoid Date: 2014-04-11 Interventions: Drug: alisertib Alisertib will |
Active, not recruiting |
Study Name: Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma Condition: Malignant Rhabdoid Tumors (MRT), Neuroblastoma Date: 2012-12-06 Interventions: Drug: LEE011 LEE011 is a small molecule inhibitor of CDK4/6. |
Withdrawn |
Study Name: Studying Biomarkers in Samples From Younger Patients With Kidney Cancer Condition: Clear Cell Renal Cell Carcinoma Congenital Mesoblastic Nephroma Date: 2012-07-15 Interventions: Other: laboratory biomarker analysis Correlative studies |
Completed |
Study Name: Studying Gene Expression in Samples From Patients With Rhabdoid Tumors Condition: Brain and Central Nervous System Tumors Kidney Cancer Date: 2012-03-10 Interventions: Genetic: DNA analysis Genetic: gene expres |